Sheila Lezcano is a Rheumatology/Immunology physician affiliated with Cedars-Sinai Medical Center. OpenAlex indexes 15 publications with 714 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
37.6%Folate Analog Metabolic Inhibitor11.1%Methotrexate91%Rasuvo9%Part D<11 patientsTNF inhibitor10.9%Humira Pen34%Enbrel Sureclick23%Enbrel17%Simponi13%Enbrel Mini7%Humira(Cf)6%Part D<11 patients+ 6 more classes in this area
Nervous system
17.2%Gabapentinoids8%Gabapentin60%Pregabalin40%Part D≥30 patientsNonsteroidal Anti-inflammatory Drug5.2%Ibuprofen83%Meloxicam17%Part D<11 patients+ 3 more classes in this area
Musculoskeletal
13.4%Nonsteroidal Anti-inflammatory Drug10%Diclofenac Sodium80%Naproxen13%Sulindac7%Part D<11 patientsRANK Ligand Inhibitor1.1%Prolia100%Part D≥18 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome
Neurogastroenterology & Motility
2011 - Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth.
PubMed
2009 - New Clinical Method for Distinguishing D-IBS from Other Gastrointestinal Conditions Causing Diarrhea: The LA/IBS Diagnostic Strategy
Digestive Diseases and Sciences
2009 - A Systematic Review of Diagnostic Tests for Small Intestinal Bacterial Overgrowth
Digestive Diseases and Sciences
2007
Similar KOLs
Other experts from the same institution or the same specialty.
Beth Karlan, MD
Cedars-Sinai Medical Center
Raj Makkar, MD
Cedars-Sinai Medical Center
Paul Noble, MD
Cedars-Sinai Medical Center
Stephen Freedland, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”